RWF_SGN33A-004

A phase 1/2 study of vadastuximab talirine (SGN-CD33A) in combination with azacitidine in patients with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High risk myelodysplastic syndrome (MDS)

This is a phase 1/2 study to evaluate the combination of vadastuximab talirine (SGN-CD33A; 33A) and azacitidine in subjects with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or high risk myelodysplastic syndrome (MDS).


Inclusion Criteria:

• Subjects with cytologically/histologically confirmed MDS according to the World Health Organization (WHO) 2008 classification.
• Previously untreated for Myelodysplastic Syndrome (MDS)
• Eligible for therapy with azacitidine.
• Life expectancy of at least 12 weeks.
Phase I/II
NCT02706899
Oncology
Hematologic
John Godwin, M.D.
Seattle Genetics Inc.
Laurie Delanty
  • Oncology and Hematology Care Eastside
  • Oncology and Hematology Care Westside